SNP specialist DxS raises funds to grow business:
This article was originally published in Clinica
Executive Summary
DxS, the Manchester, UK business that was formed by ex-AstraZeneca managers to commercialise proprietary technology to identify single nucleotide polymorphisms in individuals' DNA, has raised some £1m ($1.8m) in a second round of funding. The financing, which was led by Northern Venture Managers (of Newcastle, Reading and Edinburgh), will help DxS expand its in-house testing service for pharmaceutical companies and clinical research organisations, and also broaden its programme of licensing out the Scorpions technology. Scorpions can help predict how a patient will respond to a drug.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.